Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.
Study Type
OBSERVATIONAL
Enrollment
25
University Medical Center Ljubljana
Ljubljana, Slovenia
Haemodynamic stabilization
Decreased need for vasopressors according to vasoactive-inotropic score and increase in mean arterial pressure
Time frame: Within 12 hours after hemoadsorption
Lactate, interleukin-6, C-reactive protein and procalcitonin clearance
Time frame: Within 12 hours after hemoadsorption
Weaning from ECMO
Time frame: from day of ECMO-implant for every 24 hours until date of weaning or death, whichever came first, assessed up to 90 days
ICU length of stay
Time frame: from day of ICU-admission for every 24 hours until date of discharge or death, whichever came first, assessed up to 90 days
Hospital mortality
Time frame: from day of hospital admission until date of discharge or death, whichever came first, assessed up to 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.